High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients.
作者信息
Tréluyer Jean-Marc, Morini Jean-Pierre, Dimet Jérome, Gorin Isabelle, Rey Elisabeth, Deleuze Jean, Ceccaldi Pierre-François, Escande Jean-Paul, Pons Gérard, Dupin Nicolas
机构信息
Pharmacologie Périnatale et Pédiatrique, Groupe Hospitalier Cochin-Saint Vincent de Paul (AP-HP), Université René Descartes, 75674 Paris Cedex 14, France.
出版信息
Antimicrob Agents Chemother. 2002 Dec;46(12):4009-12. doi: 10.1128/AAC.46.12.4009-4012.2002.
Abstract
To assess the relationship between antiretroviral drug exposure and lipodystrophy, 69 human immunodeficiency virus type 1-infected patients receiving nelfinavir were investigated cross-sectionally. Lipodystrophy was defined by patients' self-report. Nelfinavir trough concentrations in plasma were significantly related to overall lipodystrophy and peripheral fat wasting scores and appeared to be an independent risk factor for lipodystrophy
摘要
相似文献
1
High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother. 2002 Dec;46(12):4009-12. doi: 10.1128/AAC.46.12.4009-4012.2002.
2
Liposuction for protease-inhibitor-associated lipodystrophy.
Lancet. 1999 Apr 10;353(9160):1244. doi: 10.1016/S0140-6736(99)01172-1.
3
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
AIDS. 1998 May 7;12(7):F51-8. doi: 10.1097/00002030-199807000-00003.
4
Lipodystrophy: results of a data evaluation of patients receiving nelfinavir-containing combination therapy.
J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):355-6. doi: 10.1097/00126334-200004010-00012.
5
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
Lancet. 2001 Feb 24;357(9256):592-8. doi: 10.1016/S0140-6736(00)04056-3.
6
Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.
Diabetes. 2002 Nov;51(11):3163-9. doi: 10.2337/diabetes.51.11.3163.
7
Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus.
J Clin Pharmacol. 1998 Aug;38(8):736-43. doi: 10.1002/j.1552-4604.1998.tb04814.x.
8
A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin.
Intern Med. 1999 Mar;38(3):302-3. doi: 10.2169/internalmedicine.38.302.
9
Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
J Clin Endocrinol Metab. 1999 Jun;84(6):1925-31. doi: 10.1210/jcem.84.6.5740.
10
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.
引用本文的文献
1
Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
Antimicrob Agents Chemother. 2006 Jun;50(6):2079-86. doi: 10.1128/AAC.01596-05.
2
Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
Antimicrob Agents Chemother. 2006 Mar;50(3):910-6. doi: 10.1128/AAC.50.3.910-916.2006.
3
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Clin Pharmacokinet. 2005;44(12):1267-78. doi: 10.2165/00003088-200544120-00005.
4
Nelfinavir: a review of its use in the management of HIV infection.
Drugs. 2005;65(15):2209-44. doi: 10.2165/00003495-200565150-00015.
5
Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
Antimicrob Agents Chemother. 2005 Feb;49(2):643-9. doi: 10.1128/AAC.49.2.643-649.2005.
6
Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?
Drugs. 2003;63(8):741-53. doi: 10.2165/00003495-200363080-00002.
本文引用的文献
1
Estimation of body fat from skinfold thickness.
Comput Methods Programs Biomed. 2001 Jun;65(3):201-6. doi: 10.1016/s0169-2607(00)00127-9.
2
Inhibition of adipocyte differentiation by HIV protease inhibitors.
J Clin Endocrinol Metab. 1999 Nov;84(11):4274-7. doi: 10.1210/jcem.84.11.6234.
3
Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations.
AIDS. 1999 Nov 12;13(16):2251-60. doi: 10.1097/00002030-199911120-00007.
4
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.
Lancet. 1999 Jun 19;353(9170):2093-9. doi: 10.1016/S0140-6736(98)08468-2.
5
Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years.
Br J Nutr. 1974 Jul;32(1):77-97. doi: 10.1079/bjn19740060.
6
The metabolic effects, and the composition of the tissue lost, in weight reduction by obese patients on treatment with fenfluramine.
Br J Pharmacol. 1973 Sep;49(1):115-20. doi: 10.1111/j.1476-5381.1973.tb08273.x.
Zotero 插件